ABVX

Abivax S.A. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K reports the unaudited interim condensed consolidated financial results for Abivax S.A. for the three months ended March 31, 2026. Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases, with its lead candidate, obefazimod, in Phase 3 trials for ulcerative colitis (UC) and Phase 2b trials for Crohn's disease (CD). The filing incorporates a press release dated May 22, 2026.

Key Financial Metrics

Expense Breakdown (Q1 2026):

• R&D Expenses: €49.5 million (26% increase vs. prior year), driven by new indications and Crohn's disease trials.
• Sales & Marketing: €1.7 million (103% increase), due to U.S. commercialization preparation.
• G&A Expenses: €6.3 million (22% decrease), primarily due to lower personnel costs and social contributions.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by 7% (€3.9 million) despite a 19% increase in operating loss. This was primarily driven by a €13.2 million swing in financial results from a loss to a gain.
• Financial Income Surge: Financial income increased to €8.0 million from a loss of €5.2 million. This was driven by €8.7 million in foreign exchange gains (revaluation of USD-denominated assets) and fair value changes on investments, offsetting interest expenses.
• Liquidity Position: Cash and cash equivalents increased significantly to €477.4 million (from €103.6 million in Q1 2025), bolstered by a €637.5 million public offering completed in July 2025.
• Debt Reduction: The company fully repaid its Kreos/Claret bond loans and converted Heights convertible notes into equity during late 2025, resulting in minimal interest expense in Q1 2026.

Guidance, Outlook, and Material Events

Subsequent Event: Royalty Certificate Repurchase
On May 7, 2026, Abivax repurchased all outstanding royalty certificates for an aggregate price of $90 million (approx. €76.5 million), paid via cash and issuance of 403,347 ADSs. This transaction is expected to result in a €43.0 million expense recognized in Q2 2026. The certificates were immediately cancelled.

Clinical Outlook:

• Ulcerative Colitis (UC): Positive Phase 3 induction results announced July 2025. Maintenance data read-out expected in Q2 2026. NDA submission to the FDA is targeted for Q4 2026.
• Crohn's Disease (CD): Phase 2b induction data read-out expected in Q4 2026.
• Long-term Data: Three-year interim data from the Phase 2a/2b open-label extension trial showed sustained clinical remission (68% at 144 weeks) with no new safety signals.

Liquidity Runway: Management expects existing cash and short-term investments (€491.6 million as of March 31, 2026) to fund operations into Q4 2027, providing a 12-month runway post-NDA submission, assuming positive maintenance trial results.

Investor Verification Checklist

• Q2 2026 Impact: Verify the recognition of the estimated €43.0 million expense related to the royalty certificate repurchase in the upcoming Q2 filing.
• Cash Runway Assumptions: Confirm that the projected cash runway into Q4 2027 holds, specifically regarding the timing of the NDA submission and the cost of scaling commercial operations.
• Clinical Milestones: Monitor the Q2 2026 read-out of the Phase 3 maintenance trial data for UC, which is critical for the planned Q4 2026 NDA submission.
• Foreign Exchange Sensitivity: Note the significant impact of FX gains on Q1 2026 financial results; assess exposure to EUR/USD fluctuations given the substantial USD-denominated cash holdings.
• Debt Status: Confirm the complete extinguishment of the Kreos/Claret and Heights financing obligations as of the reporting date.